Aortic Stiffness, Pulse Pressure, and Cerebral Pulsatility Progress Despite Best Medical Management: The OXVASC Cohort.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 3 12 2021
medline: 5 4 2022
entrez: 2 12 2021
Statut: ppublish

Résumé

Increased cerebral arterial pulsatility is associated with cerebral small vessel disease, recurrent stroke, and dementia despite the best medical treatment. However, no study has identified the rates and determinants of progression of arterial stiffness and pulsatility. In consecutive patients within 6 weeks of transient ischemic attack or nondisabling stroke (OXVASC [Oxford Vascular Study]), arterial stiffness (pulse wave velocity [PWV]) and aortic systolic, aortic diastolic, and aortic pulse pressures (aoPP) were measured by applanation tonometry (Sphygmocor), while middle cerebral artery (MCA) peak (MCA-PSV) and trough (MCA-EDV) flow velocity and Gosling pulsatility index (PI; MCA-PI) were measured by transcranial ultrasound (transcranial Doppler, DWL Doppler Box). Repeat assessments were performed at the 5-year follow-up visit after intensive medical treatment and agreement determined by intraclass correlation coefficients. Rates of progression and their determinants, stratified by age and sex, were determined by mixed-effects linear models, adjusted for age, sex, and cardiovascular risk factors. In 188 surviving, eligible patients with repeat assessments after a median of 5.8 years. PWV, aoPP, and MCA-PI were highly reproducible (intraclass correlation coefficients, 0.71, 0.59, and 0.65, respectively), with progression of PWV (2.4%; Arterial pulsatility and aortic stiffness progressed significantly after 55 years of age despite the best medical treatment. Progression of stiffness and aoPP was determined by high blood pressure, but MCA-PI predominantly reflected current aoPP. Treatments targetting cerebral pulsatility may need to principally target aortic stiffness and pulse pressure to have the potential to prevent cerebral small vessel disease.

Sections du résumé

BACKGROUND
Increased cerebral arterial pulsatility is associated with cerebral small vessel disease, recurrent stroke, and dementia despite the best medical treatment. However, no study has identified the rates and determinants of progression of arterial stiffness and pulsatility.
METHODS
In consecutive patients within 6 weeks of transient ischemic attack or nondisabling stroke (OXVASC [Oxford Vascular Study]), arterial stiffness (pulse wave velocity [PWV]) and aortic systolic, aortic diastolic, and aortic pulse pressures (aoPP) were measured by applanation tonometry (Sphygmocor), while middle cerebral artery (MCA) peak (MCA-PSV) and trough (MCA-EDV) flow velocity and Gosling pulsatility index (PI; MCA-PI) were measured by transcranial ultrasound (transcranial Doppler, DWL Doppler Box). Repeat assessments were performed at the 5-year follow-up visit after intensive medical treatment and agreement determined by intraclass correlation coefficients. Rates of progression and their determinants, stratified by age and sex, were determined by mixed-effects linear models, adjusted for age, sex, and cardiovascular risk factors.
RESULTS
In 188 surviving, eligible patients with repeat assessments after a median of 5.8 years. PWV, aoPP, and MCA-PI were highly reproducible (intraclass correlation coefficients, 0.71, 0.59, and 0.65, respectively), with progression of PWV (2.4%;
CONCLUSIONS
Arterial pulsatility and aortic stiffness progressed significantly after 55 years of age despite the best medical treatment. Progression of stiffness and aoPP was determined by high blood pressure, but MCA-PI predominantly reflected current aoPP. Treatments targetting cerebral pulsatility may need to principally target aortic stiffness and pulse pressure to have the potential to prevent cerebral small vessel disease.

Identifiants

pubmed: 34852644
doi: 10.1161/STROKEAHA.121.035560
pmc: PMC7612543
mid: EMS138589
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1310-1317

Subventions

Organisme : British Heart Foundation
ID : PG/16/38/32080
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206589/Z/17/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000372
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206589
Pays : United Kingdom

Références

Neurology. 2012 Sep 18;79(12):1215-22
pubmed: 22955138
JAMA. 2019 Aug 13;322(6):524-534
pubmed: 31408137
Int J Stroke. 2021 Aug;16(6):683-691
pubmed: 33167788
Stroke. 2018 Sep;49(9):2053-2060
pubmed: 30354991
EClinicalMedicine. 2019 Apr 24;11:34-43
pubmed: 31317131
Stroke. 2012 Oct;43(10):2631-6
pubmed: 22923446
Stroke. 2016 Jun;47(6):1669-72
pubmed: 27143273
J Cereb Blood Flow Metab. 2021 Jun;41(6):1463-1471
pubmed: 33153374
Psychol Med. 2010 Apr;40(4):603-10
pubmed: 19671212
JAMA Neurol. 2018 Jun 1;75(6):720-727
pubmed: 29507944
Stroke. 2018 Jan;49(1):62-67
pubmed: 29229726
Stroke. 2014 Feb;45(2):533-8
pubmed: 24407950
Circulation. 2006 Mar 7;113(9):1213-25
pubmed: 16476843
Stroke. 2018 Jun;49(6):1531-1533
pubmed: 29739911
Lancet. 2007 Oct 20;370(9596):1432-42
pubmed: 17928046
Stroke. 2017 Nov;48(11):3064-3072
pubmed: 29042490
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
J Neuroimaging. 2001 Jul;11(3):229-35
pubmed: 11462287
Lancet. 2005 Nov 19;366(9499):1773-83
pubmed: 16298214
Atherosclerosis. 2010 Jul;211(1):187-94
pubmed: 20226464
J Hypertens. 2019 Jun;37(6):1119-1125
pubmed: 30540658
Neurosci Biobehav Rev. 2018 Jul;90:164-173
pubmed: 29656031
J Am Heart Assoc. 2020 Jan 7;9(1):e014547
pubmed: 31902329
BMJ. 2009 Jul 06;339:b2477
pubmed: 19581317
Neurology. 2017 Jun 13;88(24):2260-2267
pubmed: 28515266
Arch Neurol. 2008 Jan;65(1):94-100
pubmed: 18195145
Eur Neurol. 2013;69(1):33-40
pubmed: 23128968

Auteurs

Alastair J S Webb (AJS)

Department of Clinical Neurosciences, Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford, United Kingdom.

Amy Lawson (A)

Department of Clinical Neurosciences, Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford, United Kingdom.

Karolina Wartolowska (K)

Department of Clinical Neurosciences, Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford, United Kingdom.

Sara Mazzucco (S)

Department of Clinical Neurosciences, Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford, United Kingdom.

Peter M Rothwell (PM)

Department of Clinical Neurosciences, Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH